Feds Rein In Use of Predictive Software That Limits Care for Medicare Advantage Patients

Software sifts through millions of medical records to match patients with similar diagnoses and characteristics and then predicts what kind of care an individual will need and for how long. New federal rules will ensure human experts are part of the process.

Social Security Overpayments Draw Scrutiny and Outrage From Members of Congress

Lawmakers are faulting the Social Security Administration for issuing billions of dollars of payments that beneficiaries weren’t entitled to receive — and then demanding the money back — in the wake of an investigation by KFF Health News and Cox Media Group.

New Medicare Advantage Plans Tailor Offerings to Asian Americans, Latinos, and LGBTQ+

As more seniors opt for Medicare Advantage, a few small insurers have begun offering plans that provide culturally targeted benefits for cohorts including Asian Americans, Latinos, and LGBTQ+ people. The approach, policy researchers say, has potential and perils.

Nuevos planes de Medicare Advantage adaptan ofertas para asiáticos, latinos y LGTBQ+

A medida que Medicare Advantage gana popularidad entre los adultos mayores, tres compañías del sur de California están lanzando nuevos planes que se enfocan en comunidades culturales y étnicas, con ofertas especiales y profesionales que hablan su idioma nativo.

As Covid Infections Rise, Nursing Homes Are Still Waiting for Vaccines

“People want covid-19 to be in the rearview mirror,” one nursing home official says. Faced with a slow rollout of the updated covid vaccines, and without state mandates for workers to get vaccinated, most skilled nursing facilities are relying on persuasion to boost vaccination rates among staff and residents.

Why the CDC Has Recommended New Covid Boosters for All

As covid-19 hospitalizations tick upward with fall approaching, the CDC says it’s time for new boosters — and not only for those at highest risk of serious disease. Here are seven things you need to know.

The Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers

The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors at risk of Alzheimer’s, experts say.